Skip to main content
Erschienen in: Osteoporosis International 12/2016

09.07.2016 | Original Article

Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries

verfasst von: J. Kjellberg, A. D. Jorgensen, P. Vestergaard, R. Ibsen, F. Gerstoft, A. Modi

Erschienen in: Osteoporosis International | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

We estimated the rate of compliance with oral bisphosphonates among Danish women and examined its association with health care resource use and cost. Approximately 30 % of Danish females aged >55 who take bisphosphonates are noncompliant, and noncompliance is significantly associated with increased health care resource use and cost.

Introduction

Two objectives of this study were to estimate the rate of oral bisphosphonate compliance among Danish women and to examine the association of noncompliance with health care resource use and cost.

Methods

Women ≥55 with an index prescription claim for an oral bisphosphonate were identified from Danish national health registries between 2003 and 2008. Compliance was measured as the medication possession ratio (MPR) during the first 12 months post-index. Cost and health care resource use were collected for the following 12 months.

Results

Among the 38,234 women meeting the study inclusion criteria, 29.9 % were noncompliant (MPR <70 %). Younger age was associated with higher odds of compliance (OR [95 % CI] 1.22 [1.15–1.29] for ages 55–64 and 1.18 [1.12–1.24] for ages 65–74; reference age group ≥75 years). Rates of all-cause health care resource use were significantly higher in noncompliant subjects: 28.9 versus 23.0 % had inpatient admissions, 16.5 versus 13.0 % had emergency room visits, and 48.7 versus 43.3 % used outpatient services (P < 0.001 for all comparisons). The total mean (SD) all-cause cost per patient (excluding office visits) was €626 (2344) and €4178 (7854), respectively. The mean (SD) osteoporosis-related cost per patient (excluding office visits) was €572 (2085) and €754 (2857) for compliant and non-compliant subjects, respectively. The compliant subjects accrued significantly lower all-cause and OP-related cost than noncompliant subjects, regardless of whether the total cost or medical cost only was considered.

Conclusions

Approximately 30 % of Danish females aged 55 or older who take bisphosphonates are noncompliant. Noncompliance is significantly associated with increased health care resource use and cost.
Literatur
4.
Zurück zum Zitat Bock O, Felsenberg D (2008) Bisphosphonates in the management of postmenopausal osteoporosis—optimizing efficacy in clinical practice. Clin Interv Aging 3(2):279–297CrossRefPubMedPubMedCentral Bock O, Felsenberg D (2008) Bisphosphonates in the management of postmenopausal osteoporosis—optimizing efficacy in clinical practice. Clin Interv Aging 3(2):279–297CrossRefPubMedPubMedCentral
6.
7.
Zurück zum Zitat Ringe JD, Christodoulakos GE, Mellstrom D, Petto H, Nickelsen T, Marin F, Pavo I (2007) Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 23(11):2677–2687. doi:10.1185/03007X226357 CrossRefPubMed Ringe JD, Christodoulakos GE, Mellstrom D, Petto H, Nickelsen T, Marin F, Pavo I (2007) Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 23(11):2677–2687. doi:10.​1185/​03007X226357 CrossRefPubMed
8.
9.
Zurück zum Zitat Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs-an analysis using national health databases. Osteoporos Int 24(10):2639–2647. doi:10.1007/s00198-013-2365-y CrossRefPubMed Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs-an analysis using national health databases. Osteoporos Int 24(10):2639–2647. doi:10.​1007/​s00198-013-2365-y CrossRefPubMed
10.
11.
Zurück zum Zitat Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23(1):223–231. doi:10.1007/s00198-011-1535-z CrossRefPubMed Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23(1):223–231. doi:10.​1007/​s00198-011-1535-z CrossRefPubMed
13.
Zurück zum Zitat Briesacher BA, Andrade SE, Yood RA, Kahler KH (2007) Consequences of poor compliance with bisphosphonates. Bone 41(5):882–887CrossRefPubMed Briesacher BA, Andrade SE, Yood RA, Kahler KH (2007) Consequences of poor compliance with bisphosphonates. Bone 41(5):882–887CrossRefPubMed
14.
Zurück zum Zitat Siris ES, Harris ST, Rosen CR, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022CrossRefPubMed Siris ES, Harris ST, Rosen CR, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013–1022CrossRefPubMed
16.
Zurück zum Zitat Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17(1):25–39PubMed Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17(1):25–39PubMed
18.
20.
Zurück zum Zitat Dreinhofer KE, Anderson M, Feron JM, Herrera A, Hube R, Johnell O, Lidgren L, Miles K, Tarantino U, Simpson H, Wallace WA (2005) Multinational survey of osteoporotic fracture management. Osteoporos Int 16(Suppl 2):S44–S53. doi:10.1007/s00198-004-1700-8 CrossRefPubMed Dreinhofer KE, Anderson M, Feron JM, Herrera A, Hube R, Johnell O, Lidgren L, Miles K, Tarantino U, Simpson H, Wallace WA (2005) Multinational survey of osteoporotic fracture management. Osteoporos Int 16(Suppl 2):S44–S53. doi:10.​1007/​s00198-004-1700-8 CrossRefPubMed
Metadaten
Titel
Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries
verfasst von
J. Kjellberg
A. D. Jorgensen
P. Vestergaard
R. Ibsen
F. Gerstoft
A. Modi
Publikationsdatum
09.07.2016
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 12/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3683-7

Weitere Artikel der Ausgabe 12/2016

Osteoporosis International 12/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.